Protocol 2256 – Liam’s conditioning for BMT

BMT #2 – Liam will receive the same conditioning that he received for his 1st transplant, plus they will be adding Anti-thymocyte globulin (ATG) for 3 days. They said this has been added to help increase his engraftment. His 2nd Bone Marrrow Transplant is scheduled for March 6, 2013.

BMT #1 – Liam received reduced intensity conditioning with Treosulfan and Fludarabine (research Protocol 2256) regimen A.

The standard protocol for reduced intensity conditioning is Fludarabine, Campath & Melphalan.

Protocol 2256 – Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Source: http://clinicaltrials.gov/show/NCT00919503

The purpose of this phase II clinical trial is to see if the combination of two chemotherapy drugs, treosulfan and fludarabine with or without low dose radiation, just prior to stem cell transplantation is safe and effective in patients with nonmalignant (noncancerous) diseases. Hematopoietic cell transplantation has been shown to be curative for many patients with nonmalignant (noncancerous) diseases such as primary immunodeficiency disorders, bone marrow failure syndromes, hemoglobinopathies, and inborn errors of metabolism (metabolic disorders). Powerful chemotherapy drugs and/or radiation are often used to condition the patient before infusion of the new healthy donor cells. The purpose of the conditioning therapy is to destroy the patient’s abnormal bone marrow which doesn’t work properly in order to make way for the new healthy donor cells which functions normally. Although effective in curing the patient’s disease, many hematopoietic cell transplantation regimens use intensive chemotherapy and/or radiation which can be quite toxic, have significant side effects, and can potentially be life-threatening. Investigators at the Fred Hutchinson Cancer Research Center in collaboration with Oregon Health & Sciences University and Medical College of Wisconsin are investigating whether a new conditioning regimen that uses less intensive drugs (treosulfan and fludarabine) with or without low dose radiation results in engraftment of the new donor cells without increased toxicities in patients with nonmalignant (noncancerous) diseases

Bone Marrow Transplant

Allogeneic HCT for Nonmalignant Inherited Disorders w/ Treosulfan (FHCRC-2256)

RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of abnormal cells. It may also stop the patient’s immune system from rejecting the donor’s stem cells. The donated stem cells may replace the patient’s immune cells and help destroy any remaining abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body’s normal cells. Giving tacrolimus, methotrexate, cyclosporine, and mycophenolate mofetil before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well giving treosulfan together with fludarabine phosphate followed by donor stem cell transplant works in treating patients with noncancerous inherited disorders.

http://www.fhcrc.org/en/treatment/clinical-trials/detail.2330.html

www.fhcrc.org

Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning – A Multicenter Trial

 

  1. Pentostatin and Lymphocyte Infusion in  - ClinicalTrials.gov

    clinicaltrials.gov/ct2/show/NCT00096161

    Jul 23, 2012 – This clinical trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem 

  2. Pentostatin and donor lymphocyte infusion for low donor t-cell 

    healthcare.utah.edu/…/pentostatin-and-donor-lymphocyte-infusion.ht…

    Pentostatin and donor lymphocyte infusion for low donor t-cell chimerism after hematopoietic cell transplantation using nonmyeloablative conditioning – a mulit 

  3. Clinical Trial Detail

    www.fhcrc.org/en/treatment/clinical-trials/detail.2330.html

    Complete title: Pentostatin and Donor Lymphocyte Infusionfor Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation Using Nonmyeloablative 

  4. 1825.00 – Clinical Trials (PDQ®) – National Cancer Institute

    www.cancer.gov/clinicaltrials/search/view?cdrid=391025…Patient

    This clinical trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.

  5. Pentostatin and Lymphocyte Infu… – ClinicalTrialFacts

    www.clinicaltrialfacts.com/…/PentostatinLymphocyte-Infusion…/Su…

    View the summary and information for: Pentostatin andLymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell 

  6. Nipent (Pentostatin) – Drug Info, Side Effects, Research, Clinical Trials

    www.druglib.com/druginfo/nipent/

    Dec 9, 2011 – Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have UndergoneDonor Stem Cell Transplant [Recruiting] 

  7. Failure of donor lymphocyte infusion to prevent graft rejection in 

    www.ncbi.nlm.nih.gov/pubmed/16864051

    by F Baron - 2006 - Cited by 3 - Related articles
    Failure of donor lymphocyte infusion to prevent graft rejection in dogs given  One of the 5 dogs given pentostatinbefore DLI maintained a stable mixed 

  8. Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection 

    clinical-trials.findthedata.org/…/Pentostatin-and-Lymphocyte-Infusio

    Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant, Accelerated Phase Chronic 

  9. Pentostatin and Donor White Blood Cells in Preventing Graft 

    www.goldbamboo.com/topic-t2293-a117460.html

    Official Title: Phase I/II Study of Pentostatin and Donor Lymphocyte Infusion in Preventing Graft Rejection in Cancer Patients With Low or Falling Donor T-Cell 

Leave a Reply